Galenika is ready for 2027
11/16/2026 • Customer news
A company with 81 years of experience, one of the leaders in Serbia’s pharmaceutical industry and with a significant presence in international markets, has made a major step forward this year by introducing modern GLP-1 therapy for obesity treatment, as well as Oli-Support products that provide nutritional support to patients throughout this process. Ricardo Vian Marques, who has been at the helm of Galenika for seven years, shared his perspective on the pharmaceutical industry and explained why the Galenika brand is stronger today than ever before.
The company you lead has achieved steady growth year after year.
Which short-term goals have you accomplished this year, and how do they align with your long-term plans?
As part of Brazil’s EMS Group, we have worked together over the past several years to develop an obesity treatment platform. One of our most significant milestones this year was the introduction of modern GLP-1 therapy for obesity treatment to the Serbian market, along with the Oli-Support line of dietary supplements designed for people who are taking care of their health and undergoing a weight management journey.
I see short-term goals as steps towards achieving our long-term strategy, rather than as separate priorities. Both the obesity treatment therapy and Oli-Support products are part of this long-term strategy.
In addition, in the first half of 2026, we launched 75 products, continued our international expansion and entered a more mature phase of ESG implementation, reflecting the company’s development, commitment to innovation and contribution to the community. Overall, I believe our greatest achievement is maintaining a steady course towards continuous innovation.
Why are obesity treatments among the most prominent topics in the pharmaceutical industry today?
According to global data from the World Health Organization, more than 1.1 billion people, or approximately one in seven people worldwide, are currently living with obesity. This number continues to rise due to changes in dietary habits, insufficient physical activity and socioeconomic factors.
Obesity is a chronic disease that requires a multidisciplinary approach, including comprehensive support in adopting healthier lifestyle habits, maintaining mental well-being and adapting one’s living environment. We have invested significant efforts in developing a platform that combines modern pharmacotherapy with nutritional support, aiming to achieve sustainable results in obesity management. Addressing obesity also means working towards better health, protecting vital organs, extending life expectancy and improving quality of life.
Obesity treatments play an exceptionally important role today because obesity is a widespread chronic disease that contributes to numerous serious health complications, including cardiovascular disease, type 2 diabetes and even certain types of cancer. Modern medicines now make it possible to achieve safe and highly effective weight reduction. This area of the pharmaceutical industry requires long-term commitment to addressing the growing global obesity epidemic.
Galenika has undergone a comprehensive transformation over the past seven years. What results have you achieved so far?
In short – transformation, stability, innovation and continuity. Looking at the broader picture, we have expanded our international operations from 10 markets in 2019 to nearly 30 markets across four continents. In Serbia, we have significantly strengthened and expanded our presence, while strategically enriching our portfolio with relevant products. Our strong market position is further confirmed by the fact that Galenika has more than 30 brands that hold leading positions in their respective categories in Serbia in terms of market share.
We have invested financial resources, time and human capital to drive progress, introduce innovations and simultaneously strengthen the company’s resilience. Furthermore, sustainability is deeply embedded in our mission and shapes the way we grow, innovate and contribute to the well-being of the communities in which we operate. I am proud of this, as it reflects our organizational maturity and our ability to think long-term.
How do you see the pharmaceutical industry in Serbia today compared to seven years ago?
The pharmaceutical industry has undergone profound changes, driven by the pandemic, geopolitical challenges and supply chain disruptions, rapid advances in biotechnology and artificial intelligence, as well as growing demands to improve the availability and accessibility of treatments. At the same time, the industry has become considerably more focused on business resilience, digitalization, patient needs and the faster development of innovative therapies. The pharmaceutical industry’s credibility has become a benchmark for other sectors as well. Health is no longer viewed merely as a medical condition but is increasingly becoming part of personal identity, while over-the-counter (OTC) products increasingly reflect consumers’ lifestyles and values. Product differentiation is no longer based solely on trust, but also on relevance to the evolving needs of modern consumers.
In Serbia, we are witnessing similar trends, accompanied by increasing alignment of the regulatory framework with European standards and continued growth of the pharmaceutical market. Today, competitiveness depends not only on product quality but increasingly on companies’ ability to innovate, ensure reliable supply, adapt to regulatory changes and maintain close relationships with patients and healthcare professionals. Pharmaceutical exports have increased significantly in recent years, while new investments are further strengthening Serbia’s role in regional and European pharmaceutical supply chains.
Looking ahead, where do you see Galenika?
I know that Galenika is ready for the future. This means that we have modernized infrastructure and technology, financial stability, highly qualified professionals, diversified revenues from both prescription (Rx) and over-the-counter (OTC) medicines, and well-established partnerships. Our commitment to consumers is reflected in our continuous efforts to make effective, high-quality and reliable medicines and therapies accessible to those who need them. We do not only address the needs of patients undergoing treatment, but also those of consumers who want to improve their quality of life.
We remain focused on maintaining stable operations while continuously investing in our people, technology and efficiency, and preserving the flexibility needed to respond promptly to market changes. Stability provides the foundation for long-term development, while innovation enables us to remain competitive. I am confident that Galenika will continue to achieve sustainable growth, built on a balance between business discipline and innovation, dedicated to people and faithful to health.
Read the full article here.
